Stock EDGE THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Edge Therapeutics Inc Nasdaq

Equities

US2798701098

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer
CI
B. Riley Lowers Price Target on PDS Biotechnology to $9 From $11, Maintains Buy Rating
MT
PDS Biotech Provides Data Update from Ongoing Versatile-002 Phase 2 Clinical Trial in Head and Neck Cancer
CI
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer
AQ
PDS Biotechnology: Q1 Earnings Snapshot
AQ
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
AQ
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NetScientific says PDS Biotech's Versamune meets endpoints
AN
PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study
MT
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
AQ
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
CI
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
AQ
Transcript : PDS Biotechnology Corporation - Special Call
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
AQ
PDS Biotechnology Announces Details of Virtual KOL Event
AQ
PDS Biotechnology Announces Details of Virtual KOL Event
AQ
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
AQ
PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer
CI
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer
AQ
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PDSB Stock
  4. Stock
  5. News Edge Therapeutics Inc